Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BANZEL vs ATIVAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.
Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 1 year of age and older (FDA-approved),Off-label: Adjunctive therapy for partial-onset seizures, generalized tonic-clonic seizures, and other refractory epilepsies
Anxiety disorders,Short-term relief of anxiety symptoms,Status epilepticus (IV),Preanesthetic medication (IM/IV)
400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.
2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.
Terminal elimination half-life is approximately 6-10 hours in adults; in pediatric patients, it is shorter (~3-6 hours). Steady-state is reached within 1-2 days.
Terminal elimination half-life is 12–18 hours (mean ~14 h). In elderly, hepatic impairment, or obesity, half-life may be prolonged up to 30 hours.
Primarily hydrolyzed by carboxylesterases in the liver to inactive metabolites (CGP 47292). Minor metabolism via CYP450 enzymes (CYP2E1, CYP3A4, CYP1A2, CYP2B6, CYP2C9, CYP2C19) but not significantly.
Hepatic via glucuronidation (UGT2B15, UGT2B7); major metabolite is lorazepam glucuronide (inactive).
Primarily renal: approximately 66% of the dose excreted in urine (30% as unchanged rufinamide, 70% as inactive metabolites). Fecal excretion: ~4%. No significant biliary excretion.
Renal: lorazepam is primarily excreted as inactive glucuronide conjugates; <1% is excreted unchanged. Total: ~95% excreted in urine, ~5% in feces.
Approximately 34% bound to plasma proteins, primarily albumin.
91% ± 2% bound to albumin. Binding is linear over therapeutic concentrations and not saturable.
Apparent volume of distribution is approximately 0.7-1.0 L/kg, indicating distribution primarily into total body water.
1.3 ± 0.2 L/kg. Vd increases with obesity, hepatic cirrhosis, and in elderly patients, indicating extensive tissue distribution.
Absolute oral bioavailability is approximately 85% (high). Food increases Cmax and AUC by about 30-40%, but this is not considered clinically significant for dosing.
Oral: 90% (range 80–100%) with first-pass metabolism negligible; Sublingual: ~90%; Intramuscular: 100% (absolute bioavailability).
Cr Cl < 30 m L/min: not recommended. Cr Cl 30-50 m L/min: maximum dose 400 mg twice daily. Cr Cl > 50 m L/min: no adjustment.
Cr Cl 10-50 m L/min: reduce dose by 50% or increase interval; Cr Cl <10 m L/min: avoid or reduce dose by 50-75% with caution.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: start 200 mg twice daily, maximum 400 mg twice daily. Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or reduce dose by 50-75% with monitoring.
Age ≥4 years: based on body weight. Starting dose: 10 mg/kg/day divided twice daily, titrate weekly by increments of 10 mg/kg/day to target maintenance 40 mg/kg/day (max 3200 mg/day). Max single dose: 1600 mg twice daily.
Children ≥6 months: 0.02-0.05 mg/kg/dose IV/IM (max 2 mg) for status epilepticus; PO: 0.05-0.1 mg/kg/dose (max 2 mg) 2-4 times daily.
No specific dose adjustment, but consider age-related renal impairment; monitor Cr Cl.
Initiate at 0.5-1 mg orally daily in divided doses; increase slowly; max 2 mg/day. IV/IM: 0.5-1 mg initial; avoid doses >2 mg due to increased sedation risk.
None
Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
May shorten QT interval; use caution with other drugs that shorten QT interval. Increased risk of suicidal thoughts/behavior. Monitor for hypersensitivity reactions (including DRESS). Central nervous system depression (dizziness, somnolence, ataxia). May decrease efficacy of hormonal contraceptives. Withdrawal seizures if abruptly discontinued. Dose adjustment needed in severe hepatic impairment.
Respiratory depression risk,Dependence and withdrawal syndrome,Abuse potential,Paradoxical reactions (hyperactivity, aggression),Use with caution in hepatic impairment,Elderly at increased risk for sedation and falls
Familial short QT syndrome (due to QT interval shortening). Hypersensitivity to rufinamide or any of its components.
Hypersensitivity to lorazepam or any benzodiazepine,Acute narrow-angle glaucoma,Severe respiratory insufficiency,Myasthenia gravis,Concurrent use with opioids (absolute unless alternative unavailable)
BANZEL should be taken with food to increase bioavailability (Cmax increases by approximately 40% and AUC by 50% compared to fasting). Avoid grapefruit juice as it may alter drug metabolism. No other food interactions are documented.
No specific food interactions. However, grapefruit juice may increase lorazepam levels (minor interaction). Avoid excessive caffeine as it may reduce sedative effects.
First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of intrauterine growth restriction, neurodevelopmental delay, and hemorrhagic disease of the newborn due to vitamin K deficiency.
First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avoid in first trimester if possible; use lowest effective dose.
Rufinamide is excreted in human milk. The milk-to-plasma ratio is approximately 0.3. Breastfeeding is not recommended due to potential adverse effects in the infant, including somnolence, poor feeding, and weight loss.
Enters breast milk; M/P ratio approximately 0.2–0.5; avoid or use with caution due to infant sedation and feeding difficulties; monitor for drowsiness and weight gain.
Pregnancy may reduce serum concentrations due to increased clearance and volume of distribution. Monitor trough levels and adjust dose to maintain therapeutic efficacy. Postpartum, monitor for toxicity as levels may rise.
Increased clearance and volume of distribution in pregnancy may necessitate dose increase; monitor clinical response; use lowest effective dose; avoid late third trimester if possible.
BANZEL (rufinamide) is an antiepileptic drug indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients ≥1 year. Titrate slowly over 2-3 weeks to reduce risk of adverse effects. Monitor for shortened QT interval; contraindicated in familial short QT syndrome. Dose adjustments needed in severe hepatic impairment. May decrease efficacy of oral contraceptives containing ethinyl estradiol. Administer with food to enhance absorption.
ATIVAN (lorazepam) is a benzodiazepine with intermediate onset and duration; useful for status epilepticus (IV) and preoperative anxiolysis. Monitor for respiratory depression, especially when combined with opioids. Not ideal for long-term anxiety due to tolerance and dependence risk. Use with caution in elderly (increased fall risk).
Take BANZEL exactly as prescribed with food to improve absorption.,Do not stop taking BANZEL suddenly; taper under medical supervision to avoid withdrawal seizures.,Inform your doctor if you have a heart condition, especially short QT syndrome.,Use effective contraception if applicable; BANZEL may reduce efficacy of oral contraceptives.,Monitor for dizziness, drowsiness, or coordination problems; avoid driving until you know how BANZEL affects you.,Report any unusual tiredness, fatigue, or signs of liver injury (yellowing skin/eyes, dark urine) immediately.
Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while taking ATIVAN.,Take exactly as prescribed; do not increase dose or stop abruptly without consulting your doctor.,May cause drowsiness, dizziness, or blurred vision.,Report any unusual mood changes, confusion, or respiratory difficulty.,This medication can be habit-forming; prolonged use may lead to dependence.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BANZEL vs ATIVAN, answered by our medical review team.
BANZEL is a Anticonvulsant that works by BANZEL (rufinamide) is a triazole derivative that modulates the activity of voltage-gated sodium channels. It prolongs the inactive state of sodium channels, thereby stabilizing neuronal membranes and inhibiting the repetitive firing of action potentials.. ATIVAN is a Benzodiazepine that works by Benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BANZEL and ATIVAN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BANZEL is: 400 mg orally twice daily, titrated by 400 mg increments every 2 weeks to a maximum of 1600 mg twice daily.. The standard adult dose of ATIVAN is: 2-3 mg orally divided 2-3 times daily; up to 10 mg/day. IV: 2 mg slow IV push, may repeat in 1-2 hours; max 10 mg/day. IM: 0.05 mg/kg (max 4 mg) 2-4 hours before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BANZEL and ATIVAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BANZEL is classified as Category C. First trimester: Increased risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiac anomalies. Second and third trimesters: Risk of . ATIVAN is classified as Category C. First trimester: Increased risk of oral clefts (odds ratio 1.5–2.0); second and third trimesters: Risk of hypotonia, respiratory depression, and withdrawal symptoms in neonate; avo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.